<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548832</url>
  </required_header>
  <id_info>
    <org_study_id>EABYBL</org_study_id>
    <nct_id>NCT02548832</nct_id>
  </id_info>
  <brief_title>Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Dyslipidemia</brief_title>
  <official_title>Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidemia, is a cardiovascular risk factor of great importance whose prevalence has&#xD;
      increased over the last decade. Part of the components of metabolic syndrome and consensus so&#xD;
      far contemplated to increased triglycerides and reduced HDL-C as part of the elements for&#xD;
      classification, which includes mixed dyslipidemia.&#xD;
&#xD;
      Currently fibrates, such as bezafibrate, are drugs whose utility in treating&#xD;
      hypertriglyceridemia is fully proven, besides reducing the risk of coronary disease. However,&#xD;
      although this treatment is safe, it is not without risks; with increased prevalence of&#xD;
      adverse effects as the dose thereof is increased or joins combination with a statin drug for&#xD;
      the treatment of mixed dyslipidemia long term.&#xD;
&#xD;
      Among the alternative therapies is berberine, which to reduce cholesterol and triglycerides&#xD;
      may be useful in combination with the bezafribrato in the treatment of mixed dyslipidemia and&#xD;
      as an option with lower cost and lower frequency of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial, double-blind, simple random assignment and parallel groups. Three study&#xD;
      groups of patients will be between 30-60 years of age diagnosed with mixed dyslipidemia with&#xD;
      failure to control medical nutrition therapy, which by simple random assignment with random&#xD;
      numbers will be assigned to one of three groups:&#xD;
&#xD;
        1. 20 patients will receive berberine, 1500 mg / day&#xD;
&#xD;
        2. Patients receive 20 bezafibrate 400 mg / day&#xD;
&#xD;
        3. 20 patients will receive combination of berberine (1500 mg / day) plus bezafibrate (400&#xD;
           mg / day) They were determined before and after the intervention: lipid profile (total&#xD;
           cholesterol, triglycerides, HDL-C, LDL-C, VLDL), weight, BMI, waist circumference,&#xD;
           glucose, blood pressure, tolerability.&#xD;
&#xD;
      Statistical analysis was performed upon the sample of subjects. Before starting the&#xD;
      statistical analysis of the groups will proceed to verify the behavior of the distribution of&#xD;
      the variables included by Z Kolmogorov-Smirnov goodness of fit. The distribution of all the&#xD;
      variables under this test is cataloged in normal or not normal, which define the type of&#xD;
      statistical test would be performed (parametric or non-parametric). However, based on the&#xD;
      sample size, non-parametric tests will be those considered most suitable for application. The&#xD;
      data obtained will be expressed and presented using measures of central tendency and&#xD;
      dispersion for quantitative (mean and standard deviation) variables and qualitative variables&#xD;
      are expressed as frequencies and percentages.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High density lipoprotein cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by Friedewall formula</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very low density lipoprotein</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by Friedewall formula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferasa</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Berberine more Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol&gt; 200 mg / dL, triglycerides&gt; 150 mg / dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bezafibrate more placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol&gt; 200 mg / dL, triglycerides&gt; 150 mg / dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine more Bezafibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol&gt; 200 mg / dL, triglycerides&gt; 150 mg / dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Berberine capsules, 500 mg 3 times daily with the first bite of each meal</description>
    <arm_group_label>Berberine more Bezafibrate</arm_group_label>
    <arm_group_label>Berberine more Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate</intervention_name>
    <description>Bezafibrate capsules, 200 mg 2 times daily with the first bite of each meal</description>
    <arm_group_label>Berberine more Bezafibrate</arm_group_label>
    <arm_group_label>Bezafibrate more placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, 500 mg 3 times daily with the first bite of each meal</description>
    <arm_group_label>Bezafibrate more placebo</arm_group_label>
    <other_name>Magnesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, 200 mg 2 times daily with the first bite of each meal</description>
    <arm_group_label>Berberine more Placebo</arm_group_label>
    <other_name>Magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. Men and women B. Accomplished age 30 to 60 years&#xD;
&#xD;
        C. Diagnosis of mixed dyslipidemia established to meet the following criteria:&#xD;
&#xD;
          -  Total cholesterol&gt; 200 mg / dL&#xD;
&#xD;
          -  Triglycerides&gt; 150 mg / dL 27 D. BMI of 25 kg / m2 to 39.9 kg / m2, weight stable over&#xD;
             the past three months, defined as a variability in the lower body weight of 5%.&#xD;
&#xD;
        E. No drug treatment for lipid profile 3 months prior to baseline. F. Women must ensure a&#xD;
        non-hormonal method to avoid pregnancy during the study period G. written information&#xD;
        consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. Removal for informed consent letter B. Loss of monitoring C. Presence of serious adverse&#xD;
        event D. Adherence to treatment &lt;80% E. Consumption of drugs known about lipid profile,&#xD;
        glucose metabolism, blood pressure and body weight during the intervention period influence&#xD;
        F. Intolerance or not tolerability or hypersensitivity to the compounds used in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esperanza Martínez-Abundis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esperanza Martínez-Abundis, PhD</last_name>
    <phone>(33) 1058-5200</phone>
    <phone_ext>34211</phone_ext>
    <email>esperanzamartnezabundi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Martínez Abundis, PhD Science</last_name>
      <phone>(33) 1058-5200</phone>
      <phone_ext>34211</phone_ext>
      <email>esperanzamartnezabundi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Esperanza Martínez-Abundis</investigator_full_name>
    <investigator_title>PhD. Esperanza Martínez-Abundis</investigator_title>
  </responsible_party>
  <keyword>Berberine</keyword>
  <keyword>Bezafibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 29, 2021</submitted>
    <returned>May 21, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

